European Primary Care Cardiovascular Society

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
EPCCS Annual CV Summit

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Consideration of SGLT2 inhibitor treatment in broader T2DM population

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.

CV safety with weight loss agent in high-risk overweight or obese patients

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No overall benefit with aspirin in a primary prevention setting of diabetes patients

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Omega-3 fatty acid supplements do not result in CV benefits

3' education - Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Management of CV risk that comes with T2DM in light of novel treatment options

10' education - Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Striking results for weight reduction in T2DM in primary care based program

3' education - Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

The evidence base for health behaviour changes

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague, Czech Republic

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Future developments in treating hyperglycemia in type 2 diabetes

3' education - Sep. 20, 2013 - London, 5-6 September 2013 - Neil Munro

Lower ACE level due to genetics or pharmacological inhibition associated with lower T2DM risk

News - Sep. 19, 2019

EASD 2019 Study shows that both natural variation in ACE concentrations and lowering blood pressure with ACE inhibitors are associated with lower risk of type 2 diabetes.

Early combination therapy gives better glucose control in newly diagnosed T2DM

News - Sep. 18, 2019

EASD 2019 The VERIFY trial demonstrated that early combination therapy using vildagliptin and metformin was superior to a sequential approach involving later intensification in new T2DM

Metformin no longer regarded as first-line therapy in new ESC/EASD Guidelines on diabetes

News - Sep. 4, 2019
As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.

ESC 2019 As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.

Cardiometabolic benefits achieved with sustained moderate calorie restriction in healthy adults

Literature - Aug. 8, 2019 - Kraus WE et al. - Lancet Diabetes Endocrinol 2019
Adults with clinically normal risk factor profiles, who were randomized to a 25% calorie restriction intervention for 2 years, showed improved insulin sensitivity and metabolic syndrome scores.

Adults with clinically normal risk factor profiles, who were randomized to a 25% calorie restriction intervention for 2 years, showed improved insulin sensitivity and metabolic syndrome scores.

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD
Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how can we modify CVD risk factors in these patients.

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD
Prof. Jacob discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.

EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

EuroPrevent 2019 Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

Original intensive glucose control does not result in CV benefit in T2DM after 15 years: no legacy effect

Literature - June 25, 2019 - Reaven PD, et al. - N Eng J Med 2019
In a follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.

In a follow-up study of VADT, original intensive glucose lowing over 5.6 years did not result in improved outcomes in T2DM patients vs. standard-therapy after 15 years, providing no evidence of a legacy effect.

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs
Profs Khunti and Hobbs discuss why CV risk needs attention in patients with diabetes, and how this risk can be mitigated. They also consider barriers that prevent optimal implementation of the evidence on effective management strategies.

EPCCS 2019 Profs Khunti and Hobbs discuss why CV risk needs attention in patients with diabetes, and how this can be mitigated. They also consider barriers that prevent optimal implementation of the evidence on effective management strategies.

Benefit of intensive BP lowering in adults with diabetes seems independent of baseline BP

Literature - May 20, 2019 - Rahman F T et al.. - Hypertension. 2019

An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.

Education, exchange, guidance and interaction during EPCCS Summit 2019

EPCCS Annual CV Summit

EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.

Slides | What's the evidence that diabetes is linked to CVD risk?

Slides (presentation) - Mar. 22, 2019 - Prof. Richard Hobbs
**EPCCS 2019** Slides prepared and presented by prof. **Richard Hobbs** (Oxford, United Kingdom), here offered as an educational service.

EPCCS 2019 Slides prepared and presented by prof. Richard Hobbs (Oxford, United Kingdom), here offered as an educational service.